Prolactinoma: A High-Yield USMLE Review

Prolactinoma is a prolactin-secreting pituitary adenoma and the most treatable of the pituitary tumors. It matters on the exam because it uniquely responds to medical therapy rather than surgery, and because distinguishing a true prolactinoma from stalk effect (and recognizing pitfalls like the hook effect) is a favorite testing theme.

Presentation

• Women present early with amenorrhea, galactorrhea, and infertility due to hyperprolactinemia suppressing the reproductive axis.
• Men present later with decreased libido and erectile dysfunction, infertility, and sometimes gynecomastia (less common than expected).
• Because men lack the obvious warning sign of amenorrhea, their tumors grow larger before diagnosis and often produce visual symptoms.
• Mass effect from a large tumor causes headache, bitemporal visual field defects from optic chiasm compression, and cavernous sinus involvement.
• Untreated chronic hyperprolactinemia leads to low estrogen and eventually osteoporosis.

Diagnosis

• Serum prolactin: markedly elevated (>200 ng/mL) strongly supports a true prolactinoma, and the level correlates with tumor size.
• MRI of the pituitary to identify and size the adenoma (microadenoma vs macroadenoma) and assess mass effect.
• Apply the prolactin-size rule to distinguish prolactinoma from stalk effect: a large tumor with only modest prolactin elevation (e.g., ~50 ng/mL) is more likely a non-functioning adenoma disrupting dopamine delivery down the stalk.
• In a macroadenoma with only mildly elevated prolactin, request serial dilution of the sample to unmask the hook effect (immunoassay saturation falsely reporting a low value).

Management

• First-line is medical therapy with dopamine agonists (cabergoline or bromocriptine), which mimic dopamine to inhibit prolactin secretion and often cause dramatic tumor shrinkage—cabergoline is preferred for weekly dosing and better tolerance.
• Bromocriptine is favored in women seeking pregnancy because it has the longer safety track record for conception; the dopamine agonist is typically stopped once pregnant, with close visual field monitoring in macroprolactinomas.
• Reserve surgery for intolerance or resistance to dopamine agonists, cystic tumors that respond poorly to medication, or patient preference.
• Observation is acceptable for an asymptomatic microprolactinoma in a postmenopausal woman with no fertility concerns or mass effect.

High-yield

• Very high prolactin (>200 ng/mL) = prolactinoma; modest elevation with a large tumor = stalk effect from a non-functioning adenoma.
• Prolactinomas are the exception among pituitary adenomas: treat medically first, not surgically.
• The hook effect—falsely low prolactin from immunoassay saturation in a giant prolactinoma—is unmasked by serial dilution.
• Prolactin inhibits GnRH, so hyperprolactinemia produces secondary (central) hypogonadism with LOW LH and FSH.
• Men present late with visual symptoms because they lack amenorrhea as an early warning sign.

Pitfalls

• Assuming any elevated prolactin means prolactinoma—stalk effect from any sellar/suprasellar mass raises prolactin by disrupting inhibitory dopamine delivery.
• Ruling out a giant prolactinoma because of a mildly elevated prolactin, missing the hook effect (order serial dilution).
• Jumping to surgery for a prolactinoma when dopamine agonists are first-line and typically effective.
• Mistaking a macroadenoma with only modestly elevated prolactin and central hypogonadism for a true prolactinoma when it is actually a non-functioning adenoma with stalk effect.